The following is a summary of “Survival in uveal melanoma patients is linked to genetic variation at HERC2 SNP rs12913832,” published in the September 2024 issue of Ophthalmology by Gelmi et al. Uveal ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on IDEAYA Biosciences (IDYA – Research Report). The associated ...

Significant regulatory news last week included the US Food and Drug Administration (FDA) granting approval for Zevra ...

The investigators assessed states’ residents’ interest in the clinician via the search topic “uveal melanoma” under the Google Trends “health” category from 2014 through January 2023. The researchers ...

IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...

Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...

Shares of California, USA-based precision medicines IDEAYA Biosciences were down 6.3% at $32.5 mid-morning after it revealed ...

Ideaya Biosciences Inc. (NASDAQ:IDYA), a precision medicine oncology company, released interim Phase 2 clinical trial data.

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) Monday announced positive interim data from a Phase 2 study evaluating darovasertib as neoadjuvant treatment for uveal melanoma (UM). Neoadjuvant therapy is ...

Now in its 6th year, MOVE FOR MELANOMA has raised over $425,000 for melanoma, non-melanoma and ocular melanoma patients across Canada TORONTO , Sept.

Ideaya Biosciences has reported positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma, or UM, as well as a successful Type C meeting with the Food and Drug ...